From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Ambroxol is not typically associated with causing tachycardia in infants, as evidenced by the most recent and highest quality study available 1. This medication, which is used as a mucolytic and expectorant to treat respiratory conditions, generally has a good safety profile in pediatric populations when used at appropriate doses. The most common side effects of ambroxol in infants include mild gastrointestinal disturbances such as nausea or upset stomach. Cardiovascular effects like tachycardia are rare and not considered a significant concern with this medication. However, as with any medication given to infants, it should only be used under medical supervision and at the prescribed dosage. If an infant taking ambroxol develops rapid heart rate or other unusual symptoms, parents should contact their healthcare provider immediately. The reason tachycardia is not a common concern with ambroxol is related to its mechanism of action, which primarily affects the respiratory system by increasing surfactant production and stimulating mucus clearance, rather than having direct effects on the cardiovascular system. Some key points to consider when evaluating the safety of ambroxol in infants include:
- The medication's efficacy in treating respiratory conditions, as demonstrated in studies such as 1
- The potential for mild gastrointestinal side effects, as noted in 1
- The lack of significant cardiovascular effects, including tachycardia, as reported in 1
- The importance of medical supervision and adherence to prescribed dosages when administering ambroxol to infants. Overall, the available evidence suggests that ambroxol is a safe and effective treatment option for infants with respiratory conditions, with a low risk of causing tachycardia or other significant side effects.